# Diabetes Research Hub — Daily Iteration Report
**Date:** 2026-08-03 (Monday — weekly sweep run)
**Agent:** scheduled-iterate

## Corpus status
- Papers: **286** (273 VETTED / 13 FLAGGED / 0 UNVETTED) — no change this run; all papers remain vetted.
- Gaps: 15 tracked (unchanged tiers).

## Step 4 — Credibility sweep (CLEAN)
- No fabricated PMIDs (none ≥ 42,000,000).
- No "zero SAE / zero rejection" claims in scripts.
- Only "curative" hits are the detector regex patterns inside `verify_before_deploy.py` (expected).

## Step 2 — Monday weekly PubMed sweep (7 target areas)
No **new PubMed-indexed PMIDs** to add as UNVETTED. Findings map to already-tracked items:

| Area | Result |
|---|---|
| LADA | Reviews + cross-sectional (Saudi/Jordan cohorts); no high-priority new PMID |
| Islet transplant | Tegoprubart/Eledon 12-pt cohort — still conference/IR only, no journal pub (queue item tracked) |
| NLRP3 diabetic kidney | MDPI IJMS 27(10):4257 (NLRP3→ferroptosis, preclinical) — DOI-real, still **no PubMed PMID** |
| Drug repurposing (generic) | Liraglutide β-cell repurposing (older PMC7237704); nothing new |
| Oxidative stress combos | COVID/metabolic-syndrome observational; NAC RCT (old) |
| Verapamil T1D | CLVer (peds) + Ver-A-T1D (adult) — adult RCT still **no journal publication** |
| Dapagliflozin + colchicine | No such diabetes trial exists (confirmed again) |

## Path re-validation (stalest distinct partial)
**metformin → cardiovascular — REMAINS PARTIALLY_VALIDATED.**
- Added 2024 umbrella review of 17 SRs (**PMID 38932855**): favorable pooled all-cause mortality OR 0.80 (0.744–0.855), CV mortality OR 0.771 (0.688–0.853) vs placebo/other agents.
- But those pooled estimates lean on observational + active-comparator data (confounding-by-indication / immortal-time bias). Strict placebo-controlled CV-endpoint RCT evidence (Griffin 2017, **PMID 28776086**) remains statistically inconclusive.
- **Deliberately NOT upgraded** — avoids overstating a first-line drug's CV benefit.

## Gap audits (4 due; all retain tier)
| Gap | Tier | Finding |
|---|---|---|
| #8 | SILVER | DIAGNODE-3 (Diamyd rhGAD65/alum) Phase 3 readout expected — but it is **recent-onset T1D, not LADA**; LADA GAD-alum+VitD pilot (NCT04262479) still no primary readout |
| #9 | EXPLORATORY | Dorzagliatin-in-LADA trial only "planned/in progress" per secondary sources; **no published human GKA-in-LADA data**; all RCT evidence remains T2D |
| #15 | BRONZE (promotion candidate) | Closest bridge = dapagliflozin + macronutrient-tailored diet RCT (PMC8166978, n=130) — macronutrient personalization, **not** biomarker/microbiome precision nutrition; gap narrowing |
| #14 | BRONZE | Berberine+Inulin LADA RCT (NCT04698330, n=240) — protocol published, **primary results still not located** |

## Step 5 — Pipeline rebuild
**39/39 offline stages [OK], 0 failed.** Network stages (`pmidverify`, `ingest`) skipped — the sandbox has no PubMed API access; these must be run on the local machine (tracked in queue).

## Git
Commit/push remains **blocked in sandbox** (OneDrive-protected `.git` locks + no GitHub auth). All research changes persist to working files on disk regardless. **User action:** from local PowerShell at the repo root — `Remove-Item .git\*.lock; git add -A; git commit -m "Daily iteration 2026-08-03"; git push`.

## Net progress this run
1 path re-validated, 4 gaps audited, weekly sweep completed, credibility clean, pipeline rebuilt. No tier changes, no new papers, no fabricated data.
